Special Drug Use-Results Survey of Onoact

Special Drug Use-Results Survey of Onoact [tachyarrhythmia, atrial fibrillation/atrial flutter in patients with cardiac dysfunction]

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080222572

Enrollment

800

Registered

2014-08-04

Start date

2014-08-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tachyarrhythmia, atrial fibrillation/atrial flutter in patients with cardiac dysfunction

Interventions

investigational material(s) Generic name etc : Onoact 50 for injection, Onoact for intravenous infusion 50mg, Onoact for intravenous infusion 150mg INN of investigational material : landiolol Therapeu

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with tachyarrhythmia, atrial fibrillation/atrial flutter under cardiac dysfunction for whom Onoact is administered

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety Safety items : Occurrence status of adverse events (including adverse drug reactions)	—

Secondary

Measure	Time frame
safety Prognosis untill 180days after Onoact treatment suc as mortality and cardiovascular events	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026